Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pulmonology

Understanding Interstitial Lung Disease (ILD)

At a Glance

Interstitial Lung Disease (ILD) is a category of over 200 lung conditions causing inflammation or scarring in the tissue supporting your air sacs. Getting an accurate diagnosis through a multidisciplinary team is essential to determine if you need anti-inflammatory or antifibrotic treatment.

It is completely normal to feel overwhelmed or even panicked when you first hear the term “Interstitial Lung Disease” (ILD). The name itself sounds complicated, and searching for it online often brings up daunting statistics. However, it is important to remember that ILD is not a single disease, but a broad category that includes over 200 different conditions [1][2]. While some forms of ILD are serious, others are highly manageable and respond well to treatment [3][4].

Understanding the Interstitium

To understand ILD, it helps to visualize how your lungs work. Your lungs contain millions of tiny air sacs (alveoli) where oxygen enters your blood. The interstitium is the thin, lace-like network of tissue that supports these air sacs and the blood vessels surrounding them [5].

In a healthy lung, this tissue is thin and elastic, allowing oxygen to pass easily into the bloodstream. In someone with ILD, this tissue becomes thick with inflammation (swelling) or fibrosis (scarring), making the lungs stiff and making it harder for oxygen to reach your blood [6][7].

Three Stabilizing Facts

As you begin this journey, keep these three essential facts in mind:

  1. A precise diagnosis takes time—and that is a good thing. Because there are hundreds of types of ILD, your doctors must be detectives [1]. Identifying the exact subtype is crucial because the treatment for one type may be completely different (or even harmful) for another [4][8].
  2. Not every ILD is the “worst-case scenario.” You may see information about Idiopathic Pulmonary Fibrosis (IPF), which is a specific, progressive form of the disease. However, many other ILDs are caused by autoimmune issues or environmental exposures and can be treated effectively with medications that reduce inflammation [3][9].
  3. The “Gold Standard” of care is a team effort. Because ILD is complex, the best way to get an accurate diagnosis is through a Multidisciplinary Discussion (MDD) [10][11]. This is a formal process where different specialists review your case together to reach a consensus [12].

Inflammation vs. Fibrosis

Most ILDs fall somewhere on a spectrum between being mostly inflammatory or mostly fibrotic. Understanding where your condition sits helps determine your treatment path:

  • Inflammatory ILD: These conditions involve an overactive immune system attacking the lung tissue. Because the primary issue is swelling and immune activity, these often respond well to immunosuppressants—medications that calm the immune system down [3][13].
  • Fibrotic ILD: These conditions involve the formation of permanent scar tissue, similar to a scar on your skin after a deep cut [3]. While scarring cannot usually be reversed, doctors use antifibrotic medications to slow down the progression of new scars [9][4].

Why the MDD Team Matters

Because the symptoms of different ILDs often look identical, one doctor’s opinion is usually not enough. The Multidisciplinary Discussion (MDD) brings together a team of experts, typically including:

  • Pulmonologists: Lung specialists who manage your overall care and symptoms [14].
  • Radiologists: Experts who specialize in reading HRCT (High-Resolution Computed Tomography) scans to identify specific patterns of scarring or inflammation [15][16].
  • Pathologists: Doctors who examine lung tissue under a microscope if a biopsy is performed [17].
  • Rheumatologists: Specialists who join the team if your lung issues are related to an autoimmune disease like rheumatoid arthritis or lupus [14][18].

This team-based approach has been proven to increase diagnostic accuracy and ensure you are started on the right therapy for your specific needs [10][19].

Common questions in this guide

What is the interstitium in the lungs?
The interstitium is the thin, lace-like network of tissue that supports your lung's air sacs and surrounding blood vessels. In ILD, this tissue becomes thick with inflammation or scarring, making it harder for oxygen to reach your bloodstream.
Is Interstitial Lung Disease (ILD) a single disease?
No, ILD is a broad category encompassing over 200 different lung conditions. Identifying the exact subtype is critical because the treatment that helps one type of ILD might be ineffective or even harmful for another.
What is the difference between inflammatory and fibrotic ILD?
Inflammatory ILD involves swelling caused by an overactive immune system attacking lung tissue, which is often treated with immunosuppressants. Fibrotic ILD involves permanent scarring in the lungs, managed with antifibrotic medications to slow new scar formation.
Why do I need a multidisciplinary team for my ILD diagnosis?
Because symptoms of different ILDs look identical, a single doctor's opinion is often not enough. A multidisciplinary discussion brings together specialists like pulmonologists, radiologists, and pathologists to review your test results together and agree on the most accurate diagnosis.
Can autoimmune diseases cause Interstitial Lung Disease?
Yes, many types of ILD are driven by underlying autoimmune issues such as rheumatoid arthritis or lupus. If you have symptoms like joint pain or severe dry eyes, your doctor may involve a rheumatologist to help determine if an autoimmune condition is causing your lung problems.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my case been reviewed in a multidisciplinary discussion (MDD)? If so, which specialists (e.g., pulmonology, radiology, pathology) were involved?
  2. 2.Does my imaging suggest a predominantly inflammatory pattern or a fibrotic (scarring) pattern?
  3. 3.Is there evidence of a 'UIP' (Usual Interstitial Pneumonia) pattern on my CT scan, and what does that mean for my diagnosis?
  4. 4.Is my ILD linked to an underlying condition, like an autoimmune disease, or is it considered 'idiopathic' (of unknown cause)?
  5. 5.What is the next step in my diagnostic journey—more blood work, a biopsy, or starting a specific treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Research Progress of Interstitial Lung Disease Based on Single-Cell Sequencing Technology.

    Li S, Zhou T, Zhang J, et al.

    Canadian respiratory journal 2026; (2026()):8863968 doi:10.1155/carj/8863968.

    PMID: 41641446
  2. 2

    Occupational interstitial lung diseases.

    Spagnolo P, Ryerson CJ, Guler S, et al.

    Journal of internal medicine 2023; (294(6)):798-815 doi:10.1111/joim.13707.

    PMID: 37535448
  3. 3

    Interstitial Lung Disease: A Review.

    Maher TM

    JAMA 2024; (331(19)):1655-1665 doi:10.1001/jama.2024.3669.

    PMID: 38648021
  4. 4

    Management of interstitial lung disease associated with connective tissue disease.

    Mathai SC, Danoff SK

    BMJ (Clinical research ed.) 2016; (352()):h6819 doi:10.1136/bmj.h6819.

    PMID: 26912511
  5. 5

    Evaluating Readability, Understandability, and Actionability of Online Printable Patient Education Materials for Cholesterol Management: A Systematic Review.

    Bhatt C, Lin E, Ferreira-Legere LE, et al.

    Journal of the American Heart Association 2024; (13(8)):e030140 doi:10.1161/JAHA.123.030140.

    PMID: 38567668
  6. 6

    Current perspective of progressive-fibrosing interstitial lung disease.

    Kishaba T

    Respiratory investigation 2022; (60(4)):503-509 doi:10.1016/j.resinv.2022.03.004.

    PMID: 35431170
  7. 7

    Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be.

    Goos T, De Sadeleer LJ, Yserbyt J, et al.

    Journal of clinical medicine 2021; (10(6)) doi:10.3390/jcm10061330.

    PMID: 33807034
  8. 8

    Interstitial Lung Disease in India. Results of a Prospective Registry.

    Singh S, Collins BF, Sharma BB, et al.

    American journal of respiratory and critical care medicine 2017; (195(6)):801-813 doi:10.1164/rccm.201607-1484OC.

    PMID: 27684041
  9. 9

    Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.

    Wilfong EM, Aggarwal R

    Therapeutic advances in musculoskeletal disease 2021; (13()):1759720X211060907 doi:10.1177/1759720X211060907.

    PMID: 34917177
  10. 10

    Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.

    Wells A, Devaraj A, Renzoni EA, Denton CP

    Seminars in respiratory and critical care medicine 2019; (40(2)):184-193 doi:10.1055/s-0039-1684020.

    PMID: 31137059
  11. 11

    Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

    Jo HE, Glaspole I, Goh N, et al.

    Respirology (Carlton, Vic.) 2019; (24(4)):361-368 doi:10.1111/resp.13427.

    PMID: 30328644
  12. 12

    Interstitial Lung Diseases in Developing Countries.

    Rivera-Ortega P, Molina-Molina M

    Annals of global health 2019; (85(1)) doi:10.5334/aogh.2414.

    PMID: 30741505
  13. 13

    Nintedanib in chILD: a small step, yes… but at least a step forward in a marathon!

    Gozal D, Kolb M

    The European respiratory journal 2023; (61(2)) doi:10.1183/13993003.01797-2022.

    PMID: 36731900
  14. 14

    The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.

    Richeldi L, Launders N, Martinez F, et al.

    ERJ open research 2019; (5(2)) doi:10.1183/23120541.00209-2018.

    PMID: 30949489
  15. 15

    High-resolution CT predictors of hypersensitivity pneumonitis.

    Rival G, Manzoni P, Lacasse Y, et al.

    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2016; (33(2)):117-23.

    PMID: 27537713
  16. 16

    Current State of Fibrotic Interstitial Lung Disease Imaging.

    Chelala L, Brixey AG, Hobbs SB, et al.

    Radiology 2025; (316(1)):e242531 doi:10.1148/radiol.242531.

    PMID: 40590695
  17. 17

    Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis.

    Wright JL, Churg A, Hague CJ, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020; (33(4)):616-625 doi:10.1038/s41379-019-0389-3.

    PMID: 31659276
  18. 18

    Role of Multidisciplinary Team Meetings in the Diagnosis and Management of Diffuse Parenchymal Lung Diseases in a Tertiary Care Hospital.

    Khan MA, Sherbini N, Alyami S, et al.

    Avicenna journal of medicine 2023; (13(4)):230-236 doi:10.1055/s-0043-1776063.

    PMID: 38144909
  19. 19

    Diffuse parenchymal lung disease.

    Tomassetti S, Ravaglia C, Poletti V

    European respiratory review : an official journal of the European Respiratory Society 2017; (26(144)) doi:10.1183/16000617.0004-2017.

    PMID: 28446601

This page provides general educational information about Interstitial Lung Disease (ILD). Always consult your pulmonologist and healthcare team for an accurate diagnosis and treatment plan specific to your condition.

Get notified when new evidence is published on Interstitial lung disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.